Counterfeit monitoring licensing

54
Republic of the Philippines Department of Health Food and Drug Administration Counterfeit Monitoring Product Research and Standards Development Division Center for Drug Regulation and Research

Transcript of Counterfeit monitoring licensing

Page 1: Counterfeit monitoring licensing

Republic of the PhilippinesDepartment of Health

Food and Drug Administration

Counterfeit Monitoring

Product Research and Standards Development DivisionCenter for Drug Regulation and Research

Page 2: Counterfeit monitoring licensing

Presentation Outline

• Counterfeit Medicines• Current Legislation on Counterfeit

medicines• Local incidence• Product Verification Process

2

Page 3: Counterfeit monitoring licensing

3

What are counterfeit drugs?

World Health Organization (SSFFC)SubstandardSpuriousFalsely LabeledFalsified andCounterfeit Medical Products

Page 4: Counterfeit monitoring licensing

4

What are counterfeit drugs?

It is a drug which is deliberately and fraudulently mislabeled with respect to identity and/or source. (World Health Organization)

Page 5: Counterfeit monitoring licensing

5

What are counterfeit drugs?

(World Health Organization)

Page 6: Counterfeit monitoring licensing

6

What are counterfeit drugs?

correct ingredients wrong ingredients

without active ingredientsinsufficient ingredients

fake packaging (World Health Organization)

Page 7: Counterfeit monitoring licensing

Republic of the PhilippinesDepartment of Health

Food and Drug Administration

Current Legislation on Counterfeit medicines

Page 8: Counterfeit monitoring licensing

8

Republic Act No. 8203

Special Law on Counterfeit Drugs• Enacted on 06 September 1996• Effective on 27 October 1996

Generally prohibits activities related to the importation, manufacture, sale, distribution or mere possession of “counterfeit drugs”

Page 9: Counterfeit monitoring licensing

Refers to medicinal products

correct ingredients but not in the amounts as provided

wrong ingredientswithout active ingredients

insufficient quantity of active ingredient reduction of the drug’s safety, efficacy, quality, strength or

purity

Counterfeit drug/medicine

9

Page 10: Counterfeit monitoring licensing

Counterfeit drug/medicineBearing without authorization the trademark, trade name or other identification mark or imprint or any likeness to that which is owned or registered in the Bureau of Patent, Trademark and Technology Transfer (BPTTT) in the name of another natural or juridical person

10

Page 11: Counterfeit monitoring licensing

Counterfeit drug/medicine

refilled in containers by unauthorized persons if the legitimate labels or marks are used;

11

Page 12: Counterfeit monitoring licensing

Counterfeit drug/medicinean unregistered imported drug product (with registered counterpart brand in the Philippines)

EXCEPT drugs brought in the country for personal use as confirmed and justified by accompanying medical records

12

Page 13: Counterfeit monitoring licensing

a drug which contains no amount of or a different active ingredient or less than eighty percent (80%) of the active ingredient it purports to possess as distinguished from an adulterated drug including reduction or loss or efficacy due to expiration.

Counterfeit drug/medicine

13

Page 14: Counterfeit monitoring licensing

Manufacture, sale, or offering for sale, donation, distribution, trafficking, brokering, exportation, or importation

Prohibited Acts

14

Page 15: Counterfeit monitoring licensing

Possession of any such counterfeit drugs

Prohibited Acts

15

Page 16: Counterfeit monitoring licensing

Forging, counterfeiting, simulating or falsely representing, or without proper authority, using any mark, stamp, tag, label or other identification mark or device authorized or required by Republic Act No. 3720

Prohibited Acts

16

Page 17: Counterfeit monitoring licensing

• Manufacturer, exporter or importer of the counterfeit drugs and their agents

• The seller, distributor, trafficker, broker or donor and their agents• The possessor of counterfeit drugs • The manager, operator or lessee of the laboratory or laboratory

facilities • The owner, proprietor, administrator or manager of the drugstore,

hospital pharmacy or dispensary, laboratory or other outlets or premises

• The registered pharmacist of the outlet where the counterfeit drug is sold or found, who sells or dispenses such drug to a third party and who has actual or constructive knowledge that said drug is counterfeit

Parties Liable

17

Page 18: Counterfeit monitoring licensing

Any person may file a complaint

IRR of 8203RULE IV: PROCEDURE IN THE FILING OF ADMINISTRATIVE COMPLAINT

Filing Of Administrative Complaint

18

Page 19: Counterfeit monitoring licensing

Filing Of Administrative Complaint

Brand owner

Affidavit of complaint

Consumer

19

Letter of complaint

Submitted together with samples

Page 20: Counterfeit monitoring licensing

Letter of complaint–Name of product–Source or the name and address of the

person from whom the product was acquired–Mode of acquisition–Reason or fact giving rise to the suspicion

Filing of Administrative Complaint

20

Page 21: Counterfeit monitoring licensing

Republic of the PhilippinesDepartment of Health

Food and Drug Administration

Local Incidence

Page 22: Counterfeit monitoring licensing

Commonly counterfeited• Popular medicines with high demand– Antihypertensive, Antibiotics

Local incidence

22

Page 23: Counterfeit monitoring licensing

23

Local incidence• Lifestyle medicines

- slimming products- products for erectile dysfunction containing ingredients

present in Viagra or Cialis

Page 24: Counterfeit monitoring licensing

• Patented medicines

Local incidence

24

Page 25: Counterfeit monitoring licensing

• Leading branded-generic medicines in the market

Local incidence

25

Page 26: Counterfeit monitoring licensing

26

Unregistered Drugs

Page 27: Counterfeit monitoring licensing
Page 28: Counterfeit monitoring licensing

• Licensing requirements for drug establishments

• Post market surveillance and enforcement

• Internal Collaboration (CDRR, RFO, CHDs, LSSC, REU)

• In-house lab testing of drug products

Strategies in place

28

Page 29: Counterfeit monitoring licensing

• Collaboration with local enforcement agencies (PNP/NBI/CIDG)

• Collaboration with stakeholders/companies

• International collaboration (ASEAN, WHO, Interpol)

• Consumer advisories to increase public awareness

Strategies in place

29

Page 30: Counterfeit monitoring licensing

• Active Surveillance– Stimulated reporting (Enforcement agencies)– Data gathering (FDA Routine PMS)

• Passive Surveillance– Consumer/Stakeholders Complaints

Source of Reports for Suspected Counterfeit Drug Products

30

Page 31: Counterfeit monitoring licensing

Republic of the PhilippinesDepartment of Health

Food and Drug Administration

Verification of Suspected Counterfeit Products

Page 32: Counterfeit monitoring licensing

Suspected Counterfeit Products

32

1• Collection/Receipt

2• Evaluation

3• Enforcement Action

Page 33: Counterfeit monitoring licensing

Sources: • FROO, CHDs• PNP/NBI• Reports from Concerned Citizen• Reports from company• Central Laboratory

33

1• Collection/Receipt of Report

Referral Letter + Sample

Page 34: Counterfeit monitoring licensing

What are the necessary information? • Information on Samples : –Name–No. of samples submitted – Batch No./ Lot No. –Manufacturer/Distributor –Date of Manufacture – Expiry date

Submission of Reports

34

Page 35: Counterfeit monitoring licensing

What are the necessary information? • Name of Source• Location/Address• Sales invoice/Official documents• If available–Date of sampling –Requesting Officer

Submission of Reports

35

Page 36: Counterfeit monitoring licensing

Center for Drug Regulation and Research

36

2•Evaluation

Page 37: Counterfeit monitoring licensing

References– Republic Act 8203

– Administrative Order No. 55 s. 1988

– Department Circular No. 2011 – 0101

– Product Dossier

Evaluation of Suspected Counterfeit Product

37

Page 38: Counterfeit monitoring licensing

Evaluation of Suspected Counterfeit Product

38

Referral Letter + Sample

Validate the information

Physical Evaluation

Can conclude?

Certification

Verify from MAH

Laboratory AnalysisYes

No

Page 39: Counterfeit monitoring licensing

Section 3 of the IRR of RA 8203The Center [Regulation Division I] may also require the registered brand-owner of the

suspected counterfeit drug to certify whether or not the suspected drug product has been manufactured, imported and/or distributed by them; or whether they own the Lot Number and Expiry Date of the same suspected drug product. The certification issued by the registered brand-owner shall be supported by the batch, production and distribution records. However, the brand-owner's certification shall be validated for evidentiary purpose.

Evaluation of Suspected Counterfeit Product

39

Verify from MAH

Page 40: Counterfeit monitoring licensing

Evaluation Results• Unregistered drug product

• Unregistered with registered counterpart brand

• Counterfeit drug product40

2•Evaluation

Page 41: Counterfeit monitoring licensing

Evaluation Results• Registered and compliant to approved label/

labeling requirements

• Registered but non-compliant to approved label/ labeling requirements

• Out of specifications

41

2•Evaluation

Page 42: Counterfeit monitoring licensing

Most common signs that a medicine is unregistered:

2•Evaluation

purchased in an unlicensed outlet/establishment and was not issued with an official receipt

Page 43: Counterfeit monitoring licensing

no name and address of any drug establishment licensed in the Philippines

no drug registration number

foreign markings

Page 44: Counterfeit monitoring licensing

Basis:• Republic Act No. 3720: Food, Drug, and

Cosmetic Act• Administrative Order No. 55 s. 1988• Bureau Circular No. 05 s. 1997

Generic Labeling Exemption

Page 45: Counterfeit monitoring licensing

Grounds:• Administrative Order No. 55 s. 1988– Primary pack is enclosed in transparent covering

and the particulars are clearly visible– Compounded by a pharmacist– Investigational Products– Donated Products

Generic Labeling Exemption

Page 46: Counterfeit monitoring licensing

Grounds:• Bureau Circular No. 05 s. 1997– Service item– Specially packed– Low volume of importation• < 500 units/ month or 6000 units/ yr

– Drug product requires special handling

Generic Labeling Exemption

Page 47: Counterfeit monitoring licensing

47

2•Evaluation

Page 48: Counterfeit monitoring licensing

48

2•Evaluation

Page 49: Counterfeit monitoring licensing

49

2•Evaluation

Page 50: Counterfeit monitoring licensing

50

2•Evaluation

Page 51: Counterfeit monitoring licensing

• Appropriate Administrative Sanctions

• Closure of Case

FROO - RFOREULSSC

51

3•Enforcement Action

Page 52: Counterfeit monitoring licensing

Republic of the PhilippinesDepartment of Health

Food and Drug Administration

National Consciousness Week Against

Counterfeit Medicines

16 – 20 November 2015

Presidential Proclamation No. 2082 dated 15 June 2010

Page 53: Counterfeit monitoring licensing

Republic of the PhilippinesDepartment of Health

Food and Drug Administration

Mamamayan Makialam, Pekeng Gamot Labanan.

Page 54: Counterfeit monitoring licensing

Republic of the PhilippinesDepartment of Health

Food and Drug Administration

Thank you!